Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells

Fig. 6

The cytotoxicity of different formulations in Raji, Daudi, and Jurkat cells. Cytotoxicity of MSNs and RMSNs on Raji cells (a), Daudi cells (b) and Jurkat cells (c). The cell viability of Raji cells treated with 100 μg/mL of MSNs or RMSNs was as high as 90%, implying that MSNs and RMSNs have good biocompatibility. Cytotoxicity of Free DOX, DMSNs and RDMSNs on Raji cells (d), Daudi cells (e) and Jurkat cells (f). Raji and Daudi cells treated with RDMSNs exhibited higher cytotoxicity compared to that of Free DOX, while Jurkat cells treated with RDMSNs exhibited lower cytotoxicity compared to that of Free DOX at the same DOX concentration. Data are presented as mean ± SD from three independent experiments.*, P < 0.05; **, p < 0.01

Back to article page